title: An unexpected but interesting response to a novel therapy for malignant extragastrointestinal stromal tumor of the mesoileum: a case report and review of the literature.
abstract: BACKGROUND
  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Extragastrointestinal stromal tumors (eGISTs) of the mesoileum are extremely rare and are usually treated with surgery combined with imatinib therapy.
  
  
  METHODS
  We present the case of a 43-year-old man who developed a large eGIST in the mesoileum. Abdominal/pelvic computed tomography revealed a large heterogeneous mass with cystic and solid components that measured 20.0 × 12.0 × 8.0 cm. Three cycles of neoadjuvant chemotherapy with epirubicin, cyclophosphamide and hydroxycamptothecin; en bloc resection; and three more cycles of adjuvant chemotherapy with the same regimen and drugs resulted in five years of disease-free survival without any symptoms.
  
  
  CONCLUSIONS
  Although imatinib treatment is usually chosen for eGISTs, resistance to imatinib remains a concern; these patients may receive neoadjuvant or adjuvant chemotherapy. In case of the former, further treatment, that is, surgery or adjuvant chemotherapy, depends on tumor response to the neoadjuvant chemotherapy. In addition, this treatment for eGIST is not only beneficial but also economical for patients compared with imatinib. A novel treatment approach that combined neoadjuvant chemotherapy, surgery and adjuvant chemotherapy resulted in long-term survival in our patient, thus showing promise as a potential therapy for eGISTs.
authors.affiliation: Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
authors.forename: Hengping
authors.initials: H
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Xingwen
authors.initials: X
authors.lastname: Li
authors.forename: Yaqiong
authors.initials: Y
authors.lastname: Kang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wei
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D046152:Gastrointestinal Stromal Tumors / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007078:Ileal Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008648:Mesoderm / Q000473:pathology*; D020360:Neoadjuvant Therapy; D012196:Review Literature as Topic; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: C527042:hydroxycamptothecinum; D015251:Epirubicin; D003520:Cyclophosphamide; D002166:Camptothecin
references.citation: Curr Mol Pharmacol. 2008 Jan;1(1):68-79
references.pmid: 20021425
references.citation: Am J Surg Pathol. 2004 Apr;28(4):479-88
references.pmid: 15087667
references.citation: Int J Surg. 2012;10(7):334-40
references.pmid: 22633986
references.citation: Urology. 2012 Mar;79(3):e36-7
references.pmid: 22386441
references.citation: Ann Surg Oncol. 2000 Oct;7(9):705-12
references.pmid: 11034250
references.citation: Int J Surg Case Rep. 2011;2(8):253-5
references.pmid: 22096744
references.citation: Pathologica. 2008 Jun;100(3):173-5
references.pmid: 18841822
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2005 May;40(5):339-41
references.pmid: 15938787
references.citation: Hum Pathol. 2002 May;33(5):466-77
references.pmid: 12094371
references.citation: Mod Pathol. 2000 May;13(5):577-85
references.pmid: 10824931
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6
references.pmid: 16046538
references.citation: Arch Pathol Lab Med. 2006 Jun;130(6):779-82
references.pmid: 16740027
references.citation: World J Surg Oncol. 2008 May 15;6:50
references.pmid: 18479530
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3898-905
references.pmid: 12228211
references.citation: Gynecol Oncol. 2009 Jun;113(3):399-401
references.pmid: 19297012
references.citation: Am J Surg Pathol. 2005 Oct;29(10):1373-81
references.pmid: 16160481
references.citation: Cancer Res. 2004 Sep 1;64(17):5913-9
references.pmid: 15342366
references.citation: J Surg Oncol. 2011 Dec;104(8):915-20
references.pmid: 21337345
references.citation: Int J Surg Pathol. 2002 Apr;10(2):81-9
references.pmid: 12075401
references.citation: World J Surg Oncol. 2012 Oct 07;10:211
references.pmid: 23039908
references.citation: Postgrad Med J. 2003 Dec;79(938):707-8
references.pmid: 14707251
references.citation: Med Oncol. 2009;26(2):233-7
references.pmid: 18777214